arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Viridian Therapeutics, Inc.

VRDN Health Care Medical Specialities
$22.92
Today
as of Sep 4, 16:56 ET
Last 30 days +16.35% Jul 27 → Sep 04
$18.45 $20.15 $21.86 $23.57 $25.27 Jul 27 Aug 04 Aug 12 Aug 19 Aug 27 Sep 04
Open
$22.62
High
$23.03
Low
$22.62
Volume
$759,913
Avg Vol
$2M
Mkt Cap
$2.5B
P/E (TTM)
—
Beta
—
52w High
$34.29
52w Low
$13.18
Div Yield
—
Shares Out
$113M

Recent Press Releases & News last 60 days · 8 items

Sep 2 · 20:00 PR Business Wire
Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
Aug 7 · 16:05 MT Newswires
Viridian Therapeutics to See 'Minimal' Revenue Growth in H2, RBC Capital Markets Says
Aug 7 · 13:28 MT Newswires
RBC Adjusts Viridian Therapeutics PT to $36 From $35, Maintains Outperform Speculative Risk Rating
▸ Show all 8 press releases & news Free account →

Overview

52-week range
$13
$34
46% of range
Avg surprise (last 3)
+7.8%
Avg reaction (last 2)
+12.5%
50% positive
Latest IV / EM
68%
EM ±10.6% · $23 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-1.61$-0.96$-0.30$0.35$1.00 Actual $-1.61Actual $-1.27Actual $-1.09Actual $-0.79Actual $-1.02Actual $-1.15Actual $-0.87Est $-0.95Actual $1.00Est $1.00Actual $-0.90Est $-1.06 MarJunSepMarJunSepMar/2025Jun/2025Mar/2026
Revenue vs Net Income Revenue Net income
$-127M$-77M$-27M$24M$74M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue May 5, 2026Mar/2026 $-0.90 $-1.06 +15.1% -3.5% +33.4% earnings
Wed Aug 6, 2025Jun/2025 $1.00 $1.00 0.0% — — earnings
Tue May 6, 2025Mar/2025 $-0.87 $-0.95 +8.4% — -8.3% earnings
Mon Sep 30, 2024Sep 2024 $-1.15 — — — — financials
Sun Jun 30, 2024Jun 2024 $-1.02 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.79 — — — — financials
Sat Sep 30, 2023Sep 2023 $-1.09 — — — — financials
Fri Jun 30, 2023Jun 2023 $-1.27 — — — — financials
Fri Mar 31, 2023Mar 2023 $-1.61 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$284,000$141,000—$71M$75,000$72,000—$86,000
Cost of revenue————————
Gross profit————————
Operating income$-126M$-116M—$-40M$-107M$-94M—$-83M
Net income$-127M$-105M—$-35M$-101M$-87M—$-77M
EPS (diluted)———————$-1.15

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents————————
Inventory————————
Total current assets$1.08B$785M$894M$572M$579M$657M$738M$767M
Total assets$1.10B$789M$899M$577M$582M$661M$742M$772M
Long-term debt———$21M$12M$21M$21M$21M
Total liabilities$435M$153M$177M$74M$67M$57M$71M$64M
Total equity$662M$636M$722M$503M$515M$604M$672M$707M

Implied volatility — last 90 days

38%149%260%371%482% Jun 07 — IV 160% · EM ±22.2%Jun 08 — IV 78% · EM ±10.3%Jun 09 — IV 70% · EM ±8.8%Jun 10 — IV 111% · EM ±13.1%Jun 11 — IV 56% · EM ±6.2%Jun 12 — IV 79% · EM ±8.1%Jun 15 — IV 99% · EM ±7.2%Jun 16 — IV 362% · EM ±21.4%Jun 17 — IV 291% · EM ±12.2%Jun 19 — IV 88% · EM ±19.5%Jun 22 — IV 78% · EM ±16.3%Jun 23 — IV 95% · EM ±19.4%Jun 24 — IV 77% · EM ±15.5%Jun 25 — IV 90% · EM ±17.5%Jun 26 — IV 96% · EM ±18.3%Jun 29 — IV 66% · EM ±11.8%Jun 30 — IV 71% · EM ±12.1%Jul 01 — IV 62% · EM ±10.3%Jul 02 — IV 38% · EM ±6.2%Jul 03 — IV 40% · EM ±6.2%Jul 06 — IV 70% · EM ±9.7%Jul 07 — IV 66% · EM ±8.7%Jul 08 — IV 69% · EM ±8.7%Jul 09 — IV 56% · EM ±6.6%Jul 10 — IV 71% · EM ±7.9%Jul 13 — IV 74% · EM ±6.2%Jul 14 — IV 103% · EM ±7.5%Jul 15 — IV 89% · EM ±5.2%Jul 16 — IV 116% · EM ±4.8%Jul 20 — IV 76% · EM ±17.9%Jul 21 — IV 67% · EM ±15.6%Jul 22 — IV 76% · EM ±17.5%Jul 23 — IV 117% · EM ±26.2%Jul 24 — IV 93% · EM ±20.6%Jul 28 — IV 105% · EM ±21.5%Aug 04 — IV 139% · EM ±24.0%Aug 06 — IV 143% · EM ±23.1%Aug 07 — IV 136% · EM ±21.2%Aug 10 — IV 132% · EM ±18.3%Aug 11 — IV 160% · EM ±21.1%Aug 12 — IV 134% · EM ±16.7%Aug 13 — IV 82% · EM ±9.7%Aug 14 — IV 159% · EM ±17.6%Aug 17 — IV 88% · EM ±7.4%Aug 18 — IV 90% · EM ±6.5%Aug 19 — IV 319% · EM ±18.9%Aug 20 — IV 483% · EM ±20.2%Aug 24 — IV 73% · EM ±15.2%Aug 25 — IV 69% · EM ±14.1%Aug 26 — IV 106% · EM ±21.2%Aug 27 — IV 104% · EM ±20.4%Aug 28 — IV 69% · EM ±13.2%Aug 31 — IV 77% · EM ±13.7%Sep 01 — IV 78% · EM ±13.4%Sep 02 — IV 130% · EM ±21.7%Sep 03 — IV 127% · EM ±20.5%Sep 04 — IV 68% · EM ±10.6%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in